BackCytoMed Therapeutics Overview

CytoMed Therapeutics Minority Interest

Track CytoMed Therapeutics's minority interest ($310K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$309221.00
↑ 442.57% YoYΔ $252229.00 vs prior year quarter

Peer trimmed avg / median

Loading

CytoMed Therapeutics Minority Interest History

Loading

CytoMed Therapeutics vs. peers: Minority Interest Comparison

Loading

CytoMed Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

CytoMed Therapeutics (GDTC) currently reports a minority interest of $310K as of December 2025. That compares with $57K in the prior-year period — up 442.6% year over year. Use the charts on this page to explore CytoMed Therapeutics's minority interest history and peer comparisons.

CytoMed Therapeutics's minority interest increased from $57K to $310K — a 442.6% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytoMed Therapeutics reported $310K in minority interest as of December 2025. That compares with $57K in the prior-year period — up 442.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current minority interest of $310K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.